Shares of Verastem Inc (NASDAQ:VSTM) have been given a consensus rating of “Buy” by the eleven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $10.94.
VSTM has been the subject of a number of recent analyst reports. Cann restated a “buy” rating and issued a $15.00 price objective (up from $6.00) on shares of Verastem in a research report on Sunday, December 10th. Cantor Fitzgerald set a $17.00 price target on Verastem and gave the stock a “buy” rating in a research report on Sunday, December 10th. Roth Capital started coverage on Verastem in a research report on Friday, December 1st. They set a “buy” rating and a $12.00 price target for the company. HC Wainwright set a $10.00 price target on Verastem and gave the stock a “buy” rating in a research report on Wednesday, December 13th. Finally, Raymond James Financial reiterated a “buy” rating on shares of Verastem in a research report on Monday, December 11th.
Verastem (NASDAQ:VSTM) traded down $0.08 during trading on Wednesday, hitting $3.45. The stock had a trading volume of 766,918 shares, compared to its average volume of 613,420. The stock has a market capitalization of $144.98, a PE ratio of -2.10 and a beta of 2.24. Verastem has a 1-year low of $1.22 and a 1-year high of $5.71. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.12 and a quick ratio of 3.12.
TRADEMARK VIOLATION WARNING: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3253814/brokerages-set-verastem-inc-vstm-price-target-at-10-36.html.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.